AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35437593 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-to-stay program
Number of subjects: 367
Study 35437687 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Cancer and Living Meaningfully (CALM) psychotherapy
Number of subjects: 14
Study 35437815 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support intervention
Number of subjects: 17
Study 35437939 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrEF (EF ≤ 40%)
Number of subjects: 4880
Study 35437939 — intervention group
Group type: EXPERIMENTAL
Intervention: HFmrEF (EF 41-49%)
Number of subjects: 4880
Study 35437939 — intervention group
Group type: COMPARATOR
Intervention: HFpEF (EF ≥ 50%)
Number of subjects: 4880
Study 35438082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training intervention (3-weekly, 4-month duration)
Number of subjects: 35
Study 35438093 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM) protein analysis
Number of subjects: 153
Study 35438093 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of 12 main proteins in 376 HM samples
Number of subjects: 153
Study 35438132 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients (KTRs)
Number of subjects: 247
Study 35438132 — intervention group
Group type: COMPARATOR
Intervention: Immunocompetent controls
Number of subjects: 247
Study 35438132 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV-positive KTRs
Number of subjects: 247
Study 35438144 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals treatment for hepatitis C
Number of subjects: 614
Study 35438144 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent IDU
Number of subjects: 614
Study 35438144 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 614
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (alpha testing)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (alpha testing for healthcare providers)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (beta testing for patients)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (beta testing for healthcare providers)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (Preparation for Decision-Making Scale for patients)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (Preparation for Decision-Making Scale for healthcare providers)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (informational support pre-test vs post-test)
Number of subjects: 0
Study 35438338 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based oncofertility support tool (instrumental support pre-test vs post-test)
Number of subjects: 0
Study 35438642 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief web-based and SMS text messaging intervention focusing on self-selected alcohol and marijuana PBS messages and motives for using PBS, delivered 3 days a week over 8 weeks
Number of subjects: 200
Study 35438642 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 200
Study 35438645 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference group (VCG)
Number of subjects: 56
Study 35438645 — intervention group
Group type: COMPARATOR
Intervention: Regular care group (RCG)
Number of subjects: 56
Study 35439028 — intervention group
Group type: EXPERIMENTAL
Intervention: Narsoplimab (OMS721), intravenous once weekly for 4-8 weeks
Number of subjects: 28
Study 35439166 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell receptor (TCR) immunosequencing assay
Number of subjects: 302
Study 35439295 — intervention group
Group type: EXPERIMENTAL
Intervention: JCAR014
Number of subjects: 129
Study 35439295 — intervention group
Group type: EXPERIMENTAL
Intervention: tisagenlecleucel (tisacel)
Number of subjects: 129
Study 35439295 — intervention group
Group type: COMPARATOR
Intervention: axicabtagene ciloleucel (axicel)
Number of subjects: 129
Study 35439298 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis, starting dose 50 ± 10 VWF:RCo IU/kg twice weekly for 12 months (prior on-demand group)
Number of subjects: 23
Study 35439298 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis based on prior plasma-derived VWF (pdVWF) weekly dose/dosing frequency for 12 months (switch group)
Number of subjects: 23
Study 35439353 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg administered orally
Number of subjects: 14
Study 35439353 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 14
Study 35439353 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 14
Study 35439899 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic clockwise rotation (Cwr) with rightward axis shift (Rws) in patients with low oxygen saturation.
Number of subjects: 160
Study 35439899 — intervention group
Group type: COMPARATOR
Intervention: Electrocardiographic findings in patients with normal oxygen saturation.
Number of subjects: 160
Study 35439899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cwr and Rws presence in patients with low oxygen saturation.
Number of subjects: 160
Study 35439899 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic findings in COVID-19 patients with dyspnea and low oxygen saturation.
Number of subjects: 160
Study 35439958 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 2003
Study 35439958 — intervention group
Group type: COMPARATOR
Intervention: Incomplete revascularization
Number of subjects: 2003
Study 35440460 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) diagnosis
Number of subjects: 1007
Study 35440460 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) diagnosis after adjusting for waist-hip ratio, diabetes, and coronary artery calcium score percentile
Number of subjects: 1007
Study 35440460 — intervention group
Group type: COMPARATOR
Intervention: No OSA diagnosis (OSA low risk)
Number of subjects: 1007
Study 35440485 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave 3
Number of subjects: 1337
Study 35440485 — intervention group
Group type: COMPARATOR
Intervention: Wave 1
Number of subjects: 1337
Study 35440485 — intervention group
Group type: COMPARATOR
Intervention: Wave 2
Number of subjects: 1337
Study 35440569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic interventions targeting AKT mutations, specific details on dosage and duration not available
Number of subjects: 0
Study 35440655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab plus radiotherapy (RT)
Number of subjects: 26
Study 35440655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab plus RT ± trastuzumab
Number of subjects: 26
Study 35440699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4)
Number of subjects: 748
Study 35440699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAI), 2 mg every 8 weeks (2q8)
Number of subjects: 748
Study 35440699 — intervention group
Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 748
Study 35440699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IAI) combined
Number of subjects: 748
Study 35441164 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac vaccine (two doses, 0-14 days apart)
Number of subjects: 434
Study 35441164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 35441227 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-fat milk (3.25% or 2% milk)
Number of subjects: 796
Study 35441227 — intervention group
Group type: COMPARATOR
Intervention: Lower-fat milk (1% or skim milk)
Number of subjects: 796
Study 35441227 — intervention group
Group type: COMPARATOR
Intervention: Frequency of cow's milk consumption
Number of subjects: 796
Study 35441530 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA with AI-QCT interpretation
Number of subjects: 0
Study 35441530 — intervention group
Group type: COMPARATOR
Intervention: Myocardial Perfusion Imaging
Number of subjects: 0
Study 35441935 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), specifically finerenone
Number of subjects: 2
Study 35441935 — intervention group
Group type: COMPARATOR
Intervention: Steroidal mineralocorticoid receptor antagonists (MRAs)
Number of subjects: 2
Study 35442106 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder stabilization surgery
Number of subjects: 764
Study 35442106 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline shoulder activity level
Number of subjects: 764
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: azacitidine + venetoclax + gemtuzumab ozogamicin (GO)
Number of subjects: 50
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: single agent PF-04518600 (OX40 agonist monoclonal antibody)
Number of subjects: 50
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: azacitidine + avelumab (anti-PD-L1 monoclonal antibody) + GO
Number of subjects: 50
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: azacitidine + venetoclax + avelumab
Number of subjects: 50
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: azacitidine + avelumab + PF-04518600
Number of subjects: 50
Study 35442137 — intervention group
Group type: EXPERIMENTAL
Intervention: glasdegib + GO
Number of subjects: 50
Study 35442194 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO intervention
Number of subjects: 45
Study 35442194 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 45
Study 35442197 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention with activity monitoring and behavioral coaching
Number of subjects: 21
Study 35442197 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral coaching (phone)
Number of subjects: 21
Study 35442197 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral coaching (in person)
Number of subjects: 21
Study 35442218 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher preoperative thalamus volume
Number of subjects: 301
Study 35442218 — intervention group
Group type: COMPARATOR
Intervention: Lower preoperative thalamus volume
Number of subjects: 301
Study 35442228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (luma/iva) for 1 month
Number of subjects: 42
Study 35442228 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurement before treatment)
Number of subjects: 42
Study 35442228 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-blocking medications
Number of subjects: 42
Study 35442238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa 1.0 mg/kg by intravenous infusion every other week for up to 144 weeks (with dose escalation to 3.0 mg/kg qow and subsequently to 3.0 mg/kg weekly permitted)
Number of subjects: 31
Study 35442254 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold (NSS) implantation
Number of subjects: 19
Study 35442403 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute IL-6R ab (tocilizumab)
Number of subjects: 21
Study 35442403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic IL-6R ab (tocilizumab)
Number of subjects: 21
Study 35442403 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 21
Study 35442530 — intervention group
Group type: EXPERIMENTAL
Intervention: vIGA-AD
Number of subjects: 1679
Study 35442713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy
Number of subjects: 123
Study 35442713 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage nivolumab/ipilimumab
Number of subjects: 123
Study 35442751 — intervention group
Group type: EXPERIMENTAL
Intervention: Returned to sport (RTS) after APM
Number of subjects: 288
Study 35442751 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS4 scores improvement in RTS patients
Number of subjects: 288
Study 35442751 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for reduced participation or performance
Number of subjects: 288
Study 35442751 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not returning to pre-injury levels of sport
Number of subjects: 288
Study 35442822 — intervention group
Group type: EXPERIMENTAL
Intervention: Motorised mobility scooter training and assessment
Number of subjects: 20
Study 35442962 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole and amoxicillin/clarithromycin
Number of subjects: 92
Study 35442962 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole and amoxicillin/levofloxacin
Number of subjects: 92
Study 35443056 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (pharmacologic inhibition of MAPK signaling)
Number of subjects: 0
Study 35443056 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF knockdown
Number of subjects: 0
Study 35443056 — intervention group
Group type: EXPERIMENTAL
Intervention: PD 0325901 (pharmacologic inhibition of MAPK signaling)
Number of subjects: 0
Study 35443056 — intervention group
Group type: COMPARATOR
Intervention: NIH3T3/TC cells
Number of subjects: 0
Study 35443252 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM1 inhibitor SGI-1776
Number of subjects: 30
Study 35443252 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of SGI-1776
Number of subjects: 30
Study 35443252 — intervention group
Group type: COMPARATOR
Intervention: PIM1 overexpression
Number of subjects: 30
Study 35443252 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM1 knockdown by siRNA
Number of subjects: 30
Study 35443258 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35443673 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 13
Study 35443673 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-EN24
Number of subjects: 13
Study 35443673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic analysis and descriptive statistics
Number of subjects: 13
Study 35443699 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource-oriented intervention (workshops and engagement in physical and creative everyday activities)
Number of subjects: 25
Study 35443783 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin treatment
Number of subjects: 0
Study 35443786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 606
Study 35443786 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 606
Study 35443947 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (4 mg P.O. twice per day, increased to 8-16 mg/d for 26 weeks, max 24 mg/day)
Number of subjects: 188
Study 35443984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 1156
Study 35443984 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 1156
Study 35443984 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antihypertensive class
Number of subjects: 1156
Study 35444059 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG (0.8 mg/kg; intravenously) + NKTR-262 (0.5 mg/kg; intratumoral)
Number of subjects: 2
Study 35444059 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG + NKTR-262
Number of subjects: 2
Study 35444059 — intervention group
Group type: COMPARATOR
Intervention: BEMPEG + RT
Number of subjects: 2
Study 35444251 — intervention group
Group type: COMPARATOR
Intervention: High-flow oxygen (HFNC)
Number of subjects: 367
Study 35444251 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 367
Study 35444251 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 367
Study 35444268 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflatoxin exposure assessed using serum AFB
Number of subjects: 1329
Study 35444421 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib (a Janus kinase-1 inhibitor)
Number of subjects: 0
Study 35444471 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of fish and fresh fruits, drinking water, and use of oral contraceptive pills
Number of subjects: 1988
Study 35444471 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking, frequent sugar intake, fizzy drinks, coffee, tea, and energy drinks
Number of subjects: 1988
Study 35444471 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1988
Study 35444567 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation-optimised video with patients giving additional information about their mostly positive therapy outcomes
Number of subjects: 142
Study 35444567 — intervention group
Group type: COMPARATOR
Intervention: Control group watching a video with patients giving information about their symptoms
Number of subjects: 142
Study 35444572 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout and emotional exhaustion
Number of subjects: 0
Study 35444683 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Genome Sequencing
Number of subjects: 0
Study 35444683 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35444875 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Erector Spinae Plane Block (ESPB)
Number of subjects: 82
Study 35444875 — intervention group
Group type: COMPARATOR
Intervention: Continuous Thoracic Epidural Analgesia (TEA)
Number of subjects: 82
Study 35444949 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative S-1 plus Oxaliplatin (peri-SOX)
Number of subjects: 151
Study 35444949 — intervention group
Group type: COMPARATOR
Intervention: Postoperative S-1 plus Oxaliplatin (post-SOX)
Number of subjects: 151
Study 35445027 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of Non-HLA-Matched Off-the-Shelf
Number of subjects: 0
Study 35445157 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBA and 5-Fluorouracil (5-FU) combination therapy
Number of subjects: 0
Study 35445157 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU) alone
Number of subjects: 0
Study 35445157 — intervention group
Group type: COMPARATOR
Intervention: PMBA alone
Number of subjects: 0
Study 35445208 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study 35445208 — intervention group
Group type: COMPARATOR
Intervention: Placebo mechanisms
Number of subjects: 0
Study 35445317 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug-coated balloon (DCB)
Number of subjects: 877
Study 35445719 — intervention group
Group type: COMPARATOR
Intervention: sarilumab 50, 100, or 200 mg plus methotrexate (MTX)
Number of subjects: 54
Study 35445719 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab 150 mg
Number of subjects: 54
Study 35445719 — intervention group
Group type: EXPERIMENTAL
Intervention: tocilizumab 162 mg
Number of subjects: 54
Study 35445719 — intervention group
Group type: EXPERIMENTAL
Intervention: sarilumab treatment
Number of subjects: 54
Study 35445948 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium-166
Number of subjects: 0
Study 35446110 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic nocturnal polyuria (NP)
Number of subjects: 10190
Study 35446110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder outlet obstruction (NPBOO) in men
Number of subjects: 10190
Study 35446110 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (NPOAB) in women
Number of subjects: 10190
Study 35446110 — intervention group
Group type: EXPERIMENTAL
Intervention: Bother associated with nighttime voiding
Number of subjects: 10190
Study 35446411 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper airway stimulation
Number of subjects: 42
Study 35446440 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density mapping system and advanced point-by-point RF ablation technology
Number of subjects: 300
Study 35446440 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ablation monitoring with ambulatory event monitoring and Holter monitoring
Number of subjects: 300
Study 35446440 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured ablation workflow with advanced algorithms and local impedance technology
Number of subjects: 300
Study 35446674 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenovela Educational Intervention
Number of subjects: 0
Study 35446677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 4131
Study 35446677 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteriorating trajectory group
Number of subjects: 4131
Study 35446677 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy behaviors
Number of subjects: 4131
Study 35446677 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk cluster with severe, persistent postchemotherapy QOL deterioration
Number of subjects: 4131
Study 35446854 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based platform for predicting QoL issues and suggesting interventions
Number of subjects: 0
Study 35446894 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-aminoethyl dihydrogen phosphate normalized by taurine concentrations
Number of subjects: 50
Study 35446894 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 35446934 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-CAR T-cell therapy
Number of subjects: 12
Study 35446944 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg BID day 1, 800 mg BID days 2-10)
Number of subjects: 149
Study 35446944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 35447145 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream, applied 3 times a week for 16 weeks
Number of subjects: 24
Study 35447145 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod cream
Number of subjects: 24